Trulieve Lands on Wall Street
Trulieve’s NYSE debut marks a historic moment for the U.S. cannabis industry, bringing a plant-touching operator onto a major American stock exchange for the first time.
On June 10, 2026, Trulieve Cannabis Corp. became the first U.S. plant-touching cannabis operator to list on the New York Stock Exchange (NYSE), trading under the ticker symbol TRLV.
This milestone marks the first time a U.S. plant-touching cannabis operator has gained a listing on a major U.S. stock exchange. For years, major Wall Street institutions maintained a strict barrier against US operators due to the federal illegality of the plant.
Trulieve’s successful uplisting bypasses this financial ceiling through a combination of rigorous corporate restructuring and a rapidly evolving federal regulatory landscape.
Navigating NYSE Compliance
To satisfy the strict compliance mandates of the NYSE, Trulieve had to architect a creative corporate separation of its core business assets.
Because cannabis remained federally illegal, major U.S. exchanges historically avoided listing companies directly involved in state-licensed adult-use cannabis operations.
To satisfy NYSE requirements, Trulieve completed a corporate restructuring that separated adult-use operations from its remaining consolidated business, according to reports.
Following the restructuring, the company’s consolidated operations consisted exclusively of state-licensed medical cannabis facilities, a change that helped align the business with the regulatory framework created by the federal reclassification of medical marijuana.
“As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base, increase liquidity and raise awareness for the benefits of medical marijuana,” Trulieve founder and CEO Kim Rivers said in a statement.
The Policy Catalysts
While corporate structuring provided the framework, federal policy shifts provided the momentum. The strategy gained significant legal backing following the Department of Justice’s formal progression toward moving cannabis from Schedule I to Schedule III of the Controlled Substances Act.
This administrative shift is poised to have significant implications for the cannabis industry’s financial health:
- Tax Code Relief: Under Schedule I or II status, cannabis businesses are subject to Section 280E of the Internal Revenue Code, which prohibits companies trafficking in controlled substances from deducting ordinary business expenses.
- Operating Deductions: Industry observers expect the move to Schedule III to eliminate the burden of Section 280E for qualifying medical cannabis businesses, allowing operators to deduct ordinary business expenses that were previously disallowed under federal tax rules. However, the full impact will depend on how the new regulatory framework is implemented.
Trulieve’s Position Entering Wall Street
Trulieve’s transition to a major asset exchange is backed by a balance sheet that includes substantial cash reserves and positive adjusted EBITDA.
According to financial data from the first quarter of 2026, the operator maintained steady revenue streams and a substantial retail footprint primarily anchored by strong medical markets like Florida.
Total Revenue: $287 Million
Adjusted EBITDA: $100 Million
Gross Margin: 59%
Cash Reserves: $353 Million
Retail Footprint: 206 medical dispensaries & 3.5M+ sq. ft. of cultivation
Access to the NYSE allows Trulieve to tap into institutional capital, mutual funds, and credit facilities that were previously out of reach due to custody restrictions associated with OTC-listed stocks.
Implications for the MSO Landscape
The listing is likely to be closely watched by other multi-state operators evaluating whether similar restructuring strategies may provide access to major U.S. exchanges.
In anticipation of potential federal shifts and uplisting opportunities, peer MSOs have in fact actively adjusted their capital structures. Companies like Curaleaf Holdings and Verano Holdings have previously executed strategic corporate maneuvers, including share consolidations and reverse stock splits, to optimize their equity frameworks for institutional custody.
As capital markets adapt to the reality of a domestic exchange listing a plant-touching operator, the gap between traditional corporate finance and the American cannabis sector will hopefully continue to close.
Read more from Soft Secrets:
Disclaimer: Soft Secrets provides industry news, regulatory updates, and market analysis for educational and informational purposes only. Content should not be construed as financial, legal, or investment advice. Readers should consult with a professional finance or legal expert before making any investment decisions.
S
Stephen Andrews
